Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes

International Journal of Molecular Medicine

Volumn 27, Issue 5, 2011, Pages 619-624

  Toyoda, Mako ^a   Kitaoka, Akira ^a   Machida, Kazuyuki ^a   Nishinakagawa, Takuya ^a   Yada, Ryoko ^b   Kohjima, Motoyuki ^b   Kato, Masaki ^c   Kotoh, Kazuhiro ^c   Sakamoto, Naoya ^d   Shiota, Goshi ^e   Nakamuta, Makoto ^b   Nakashima, Manabu ^a   Enjoji, Munechika ^a,b  

^a FUKUOKA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e TOTTORI UNIVERSITY   (Japan)

Author keywords

Cannabinoid; Cannabinoid receptor 1; Hepatitis C virus; Huh7; Replicon; Triglyceride

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ALPHA INTERFERON; CANNABINOID; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; TRIACYLGLYCEROL;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; LIPID STORAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS GENE;

ANTIVIRAL AGENTS; ARACHIDONIC ACIDS; CELL LINE, TUMOR; DOXYCYCLINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; LIPID METABOLISM; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; TRIGLYCERIDES; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 79952976755     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.622     Document Type: Article

References (29)

1. Parfieniuk A and Flislak R: Role of cannabinoids in chronic liver diseases. World J Gastroenterol 14: 6109-6114, 2008.
2. Mallat A and Lotersztajn S: Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis. Diabetes Metab 34: 680-684, 2008.
3. Caraceni P, Domenicali M, Giannone F and Bernardi M: The role of the endocannabinoid system in liver diseases. Best Pract Res Clin Endocrinol Metab 23: 65-77, 2009.
4. Purohit V, Rapaka R and Shurtleff D: Role of cannabinoids in the development of fatty liver (steatosis). AAPS J 12: 233-237, 2010.
5. Kunos G and Osei-Hyiaman D: Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 294: G1101-G1104, 2008.
6. Osei-Hyiaman D, Depetrillo M, Pacher P, et al: Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298-1305, 2005. (Pubitemid 40629049)
7. Osei-Hyiaman D, Liu J, Zhou L, et al: Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118: 3160-3169, 2008.
8. Van Gaal L, Pi-Sunyer X, Despres JP, McCarthy C and Scheen A: Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 (Suppl. 2): S229-S240, 2008.
9. Gary-Bobo M, Elachouri G, Gallas JF, et al: Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46: 122-129, 2007. (Pubitemid 47171928)
10. Ravinet-Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP and Soubrie P: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284: R345-R353, 2003. (Pubitemid 36120150)
11. Kojima M, Kato N, Hirano D, Ochi T, Nii A, Shinjo K and Eda H: Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by Concanavalin A. Hepatol Res 39: 408-414, 2009.
12. Mendez-Sanchez N, Zamora-Valdes D, Pichardo-Bahena R, et al: Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int 27: 215-219, 2007. (Pubitemid 46680725)
13. Lotersztajn S, Teixeira-Clerc F, Julien B, et al: CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 153: 286-289, 2008.
14. Teixeria-Clerc F, Belot MP, Manin S, et al: Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology 52: 1046-1059, 2010.
15. Yamaguchi A, Tazuma S, Nishioka T, Ohishi W, Hyogo H, Nomura S and Chayama K: Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci 50: 1361-1371, 2005. (Pubitemid 41184770)
16. Fukasawa M, Tanaka Y, Sato S, et al: Enhancement of de novo fatty acid biosynthesis in hepatic cell line Huh7 expressing hepatitis C virus core protein. Biol Pharm Bull 29: 1958-1961, 2006.
17. Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A and Negro F: The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 45: 1164-1171, 2007. (Pubitemid 46775778)
18. Hezode C, Zafrani ES, Roudot-Thoraval F, et al: Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 134: 432-439, 2008. (Pubitemid 351173051)
19. Marusawa H, Hijikata M, Chiba T and Shimotohno K: Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-κB activation. J Virol 73: 4713-4720, 1999. (Pubitemid 29246730)
20. Yokota T, Sakamoto N, Enomoto N, et al: Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 4: 602-608, 2003. (Pubitemid 36939952)
21. Tanabe Y, Sakamoto N, Enomoto N, et al: Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-α. J Infect Dis 189: 1129-1139, 2004. (Pubitemid 38457235)
22. Julien B, Grenard P, Teixeira-Clerc F, et al: Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128: 742-755, 2005. (Pubitemid 40585376)
23. Teixeira-Clerc F, Julien B, Grenard P, et al: CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12: 671-676, 2006. (Pubitemid 43865236)
24. Mallat A and Lotersztajin S: Endocannabinoids and liver disease. Am J Physiol 294: G9-G12, 2008.
25. Mallat A, Hezode C and Lotersztajn S: Environmental factors as disease accelerators during chronic hepatitis C. J Hepatol 48: 657-665, 2008.
26. Bátkai S, Jarai Z, Wagner JA, et al: Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7: 827-832, 2001. (Pubitemid 32691638)
27. Fernandez-Rodriguez CM, Romero J, Petros TJ, et al: Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int 24: 477-483, 2004.
28. Siegmund SV, Qian T, de Minicis S, et al: The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J 21: 2798-2806, 2007. (Pubitemid 47372747)
29. Pacher P, Bátkai S and Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462, 2006. (Pubitemid 44394908)